miRNAs Related to Immune Checkpoint Inhibitor Response: A Systematic Review DOI Open Access
José Luis García‐Gimenez, Wiam Saadi, Ángel Ortega

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(3), P. 1737 - 1737

Published: Feb. 1, 2024

The advent of immune checkpoint inhibitors (ICIs) has represented a breakthrough in the treatment many cancers, although high number patients fail to respond ICIs, which is partially due ability tumor cells evade system surveillance. Non-coding microRNAs (miRNAs) have been shown modulate evasion cells, and there thus growing interest elucidating whether these miRNAs could be targetable or proposed as novel biomarkers for prognosis response ICIs. We therefore performed an extensive literature analysis evaluate clinical utility with confirmed direct relationship As result this systematic review, we stratified miRNA landscape into (i) whose levels directly (ii) expression modulated by (iii) that elicit toxic effects participate immune-related adverse events (irAEs) caused

Language: Английский

BTLA biology in cancer: from bench discoveries to clinical potentials DOI Creative Commons
Anna Andrzejczak, Lidia Karabon

Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)

Published: Jan. 17, 2024

Abstract Immune checkpoints play a critical role in maintaining the delicate balance of immune activation order to prevent potential harm caused by excessive activation, autoimmunity, or tissue damage. B and T lymphocyte attenuator (BTLA) is one crucial checkpoint, regulating stimulatory inhibitory signals responses. Its interaction with herpes virus entry mediator (HVEM) plays an essential negatively responses, thereby preserving homeostasis. In cancer, abnormal cells evade surveillance exploiting like BTLA. Upregulated BTLA expression linked impaired anti-tumor immunity unfavorable disease outcomes. preclinical studies, BTLA-targeted therapies have shown improved treatment outcomes enhanced antitumor immunity. This review aims provide in-depth understanding BTLA’s biology, its various cancers, as prognostic factor. Additionally, it explores latest research on blockade cancer immunotherapy, offering hope for more effective treatments.

Language: Английский

Citations

19
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach DOI Creative Commons
Subhamay Adhikary, Surajit Pathak, Vignesh Palani

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(1), P. 217 - 217

Published: Jan. 18, 2024

Immunotherapy is now established as a potent therapeutic paradigm engendering antitumor immune response against wide range of malignancies and other diseases by modulating the system either through stimulation or suppression components such CD4+ T cells, CD8+ B monocytes, macrophages, dendritic natural killer cells. By targeting several checkpoint inhibitors blockers (e.g., PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIM-3) expressed on surface monoclonal antibodies polyclonal have been developed already translated clinically. In addition, cell-based, CAR cell therapies also shown to be promising effective immunotherapeutic approaches. particular, therapy has benefited from advancements in CRISPR-Cas9 genome editing technology, allowing generation modified cells with enhanced immunity. However, emerging SARS-CoV-2 infection could hijack patient’s releasing pro-inflammatory interleukins cytokines IL-1β, IL-2, IL-6, IL-10, IFN-γ TNF-α, respectively, which can further promote neutrophil extravasation vasodilation blood vessels. Despite significant development advanced technologies, after certain period treatment, cancer relapses due resistance immunotherapy. Resistance may primary (where tumor do not respond treatment), secondary acquired develop gradually ICIs therapy). this context, review aims address existing technologies mechanisms drugs, explain impact COVID-19 treatment. we will discuss what future implementation these strategies drug resistance. Finally, emphasize practical steps lay groundwork for enlightened policy intervention resource allocation care patients.

Language: Английский

Citations

10
Soluble B7 and TNF family in colorectal cancer: Serum level, prognostic and treatment value DOI

Mina Monfared,

Sina Nazmi,

Forough Parhizkar

et al.

Human Immunology, Journal Year: 2025, Volume and Issue: 86(2), P. 111232 - 111232

Published: Jan. 9, 2025

Language: Английский

Citations

1
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer DOI
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao

et al.

BioDrugs, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

Language: Английский

Citations

1
Exploring a specialized programmed-cell death patterns to predict the prognosis and sensitivity of immunotherapy in cutaneous melanoma via machine learning DOI

Leyang Xiao,

Ruifeng He, Kaibo Hu

et al.

APOPTOSIS, Journal Year: 2024, Volume and Issue: 29(7-8), P. 1070 - 1089

Published: April 14, 2024

Language: Английский

Citations

8
Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review DOI Creative Commons

Fatemeh Eskandari-Malayeri,

Marzieh Rezaei

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Oct. 5, 2022

The tumor microenvironment (TME) is a significant contributor to cancer progression containing complex connections between cellular and chemical components provides suitable substrate for growth development. Growing evidence shows targeting cells while ignoring the surrounding TME not effective enough overcome disease. Fibroblasts are essential sentinels of stroma that due certain conditions in TME, such as oxidative stress local hypoxia, become activated, play prominent role physical support enhancement tumorigenesis. Activated fibroblasts defined cancer-associated (CAFs), crucial regulating biological behavior tumors, metastasis drug resistance. CAFs highly heterogeneous populations have different origins and, addition their supporting stromal cells, multiple immunosuppressive functions via membrane secretory patterns. secretion cytokines/chemokines, interactions mediate recruitment regulatory immune reprogramming an function immature myeloid just few examples how contribute escape tumors through various direct indirect mechanisms on specific cell populations. Moreover, directly abolish cytotoxic lymphocytes. activation overexpression inhibitory checkpoints (iICPs) or ligands compartments one main inactivate tumor-infiltrating lymphocytes lesions. also players induction expression iICPs suppression response TME. Based available studies, CAF subsets could modulate two ways; by activated production soluble then upregulation With focus CAFs' roles well use immunotherapy diagnostics, we present evolving understanding mechanism this review. Understanding complete picture will help develop new strategies improve precision therapy.

Language: Английский

Citations

25
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses? DOI Open Access
Michael Kuske, Maximilian Haist,

T. Jung

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(7), P. 1710 - 1710

Published: March 28, 2022

The approval of immune checkpoint inhibitors (ICI) that serve to enhance effector T-cell anti-tumor responses has strongly improved success rates in the treatment metastatic melanoma and other tumor types. currently approved ICI constitute monoclonal antibodies blocking cytotoxic T-lymphocyte-associated protein (CTLA)-4 anti-programmed cell death (PD)-1. By this, T-cell-inhibitory CTLA-4/CD80/86 PD-1/PD-1L/2L signaling axes are inhibited. This leads sustained activity circumvents evasion cells, which frequently upregulate PD-L1 expression modulate molecule on leukocytes. As a result, profound clinical observed 40–60% patients. Despite pivotal role T cells for triggering immunity, mounting evidence indicates efficacy may also be attributable types than cells. In particular, emerging research shown impacts innate such as myeloid natural killer lymphoid amplify tumoricidal functions beyond thus improves efficacy. Effects non-T additionally explain, part, character extent adverse effects associated with treatment. Deeper knowledge these is required further develop terms responsiveness patients treatment, overcome resistance alleviate effects. this review we give an overview into known immunomodulatory compartment.

Language: Английский

Citations

24
Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types DOI Creative Commons
Lirui Dai, Xuyang Guo, Zhe Xing

et al.

BMC Cancer, Journal Year: 2023, Volume and Issue: 23(1)

Published: Jan. 30, 2023

CD276 (also known as B7-H3) is one of the most important immune checkpoints CD28 and B7 superfamily, its abnormal expression closely associated with various types cancer. It has been shown that able to inhibit function T cells, this gene may potentially be a promising immunotherapy target for different cancer.Since few systematic studies have published on role in cancer date, present study employed single-cell sequencing bioinformatics methods analyze patterns, clinical significance, prognostic value, epigenetic alterations, DNA methylation level, tumor cell infiltration functions In order potential underlying mechanism glioblastoma (GBM) assess LinkedOmics database was used explore biological co-expression pattern GBM, Gene Ontology (GO) Kyoto Encyclopedia Genes Genomes (KEGG) enrichment analyses were performed. addition, simple validation above performed using reverse transcription-quantitative (RT-q)PCR assay.The results revealed highly expressed, often poorer survival prognosis, majority found infiltration, checkpoint genes immunoregulatory interactions between lymphoid non-lymphoid cell. also network exerts wide influence activation GBM. The positively correlated neutrophil-mediated immunity, although it negatively level neurotransmitters, neurotransmitter transport regulation neuropeptide signaling pathways noteworthy significantly higher GBM compared normal controls according RT-qPCR analysis, network, chemotherapeutic drug sensitivity further explored. conclusion, findings strongly expressed poor prognosis cancer, including T-cell genes, immunomodulatory lymphocytes cells.Taken together, based our roles cancers, especially serve biomarker

Language: Английский

Citations

14
Trispecific antibodies for cancer immunotherapy DOI Open Access

Yin Yao,

Yiyin Hu,

Fei Wang

et al.

Immunology, Journal Year: 2023, Volume and Issue: 169(4), P. 389 - 399

Published: March 1, 2023

Abstract Despite the clinical success of monoclonal and bispecific antibodies, there are still limitations in therapeutic effect malignant tumours, such as low response rate, treatment resistance, so on, inspiring exploration trispecific antibodies (TsAbs). TsAbs further improve safety efficacy has great potential through three targets combination formats optimization. This article reviews development history target features TsAbs. Although challenges application TsAbs, it is undeniable that may be a breakthrough antibody drugs.

Language: Английский

Citations

14
Modern cancer therapy: cryoablation meets immune checkpoint blockade DOI Creative Commons
Qi Liu, Chun‐yang Zhang, Xuxin Chen

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Feb. 7, 2024

Cryoablation, as a minimally invasive technology for the treatment of tumors, destroys target tumors with lethal low temperatures. It simultaneously releases large number tumor-specific antigens, pro-inflammatory cytokines, and nucleoproteins, known “danger signals”, activating body’s innate adaptive immune responses. However, tumor cells can promote inactivation effector by reprogramming checkpoints, leading to insufficiency these antigens induce an response capable eradicating tumor. Immune checkpoint blockers rejuvenate exhausted T blocking checkpoints that programmed death cells, are therefore considered promising therapeutic strategy enhance effects cryoablation. In this review, we provide detailed explanation immunological mechanisms cryoablation articulate theoretical basis research progress cancer combined blockers. Preliminary data indicates exhibits good synergy has been proven be safe effective.

Language: Английский

Citations

6